Form 8-K · Current Report · Filed 2024-02-22
Guardant Health Reports 2023 Financial Results and Provides 2024 Outlook
Guardant Health, Inc. reported financial results for the fourth quarter and full year of 2023, showing a 25% increase in annual revenue driven by a 39% growth in clinical volume. The company reported $563.9 million in full-year revenue and expects 2024 revenue in the range of $655 to $670 million. Guardant Health also highlighted operational highlights for 2023, including an improved ASP with Guardant360 LDT CMS reimbursement and collaborations with leading oncology practices. The company ended 2023 with $1.2 billion in cash, cash equivalents, and marketable debt securities.
- Filer
- Guardant Health Inc. GH · NASDAQ
- Filed
- Accession
- 0001576280-24-000039
- CIK
- 0001576280
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$22.66
Next session
-14.3%
Since filing
+614.9%
Latest close
$161.99
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from GH reporting the same item, with the next session's move:
Exhibits (1)
About Guardant Health Inc.
Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.
Never miss another GH filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.